CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx to Host Investor Day on October 15, 2024 — Oct 8th, 2024

BRISBANE, Calif., October 08, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx to Host Investor Day on October 15, 2024 — Oct 8th, 2024

BRISBANE, Calif., October 08, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing — Oct 8th, 2024

DOJ Concludes Investigation and Declines to Prosecute BRISBANE, Calif., October 08, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differen...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx to Host Investor Day on October 15, 2024 — Oct 8th, 2024

BRISBANE, Calif., October 08, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing — Oct 8th, 2024

DOJ Concludes Investigation and Declines to Prosecute BRISBANE, Calif., October 08, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differen...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Oct 11th, 2024

BRISBANE, Calif., October 11, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

CareDx Appoints Jing Huang Chief Data and AI Officer — Oct 9th, 2024

BRISBANE, Calif., October 09, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant pat...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... — Oct 9th, 2024

Revenue: $92.3 million for Q2 2024, up 31% year-over-year. Testing Services Revenue: $70.9 million, up 33% year-over-year. Adjusted Testing Services Revenue: $57.7 million, up 21% year-over-year. Patient and Digital Solutions Revenue: $10.7 million, up 19% year-over-year. Product Revenue: ...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting — Oct 21st, 2024

New Data Highlights Latest Advancements to AlloSeq Tx Used in Solid Organ and Stem Cell Transplant HLA Typing CareDx Introduces Newest Enhancements to QTYPE for Rapid Deceased Donor HLA Typing BRISBANE, Calif., October 21, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transp...

CareDx Reports Preliminary Financial Results for Third Quarter 2024 — Oct 15th, 2024

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 BRISBANE, Calif., October 15, 2024--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c...